Eagle Asset Management Inc. increased its position in Zoetis Inc. (NYSE:ZTS) by 8.4% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 808,160 shares of the company’s stock after purchasing an additional 62,538 shares during the period. Eagle Asset Management Inc. owned 0.17% of Zoetis worth $51,520,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of ZTS. Great West Life Assurance Co. Can increased its holdings in shares of Zoetis by 9.9% in the third quarter. Great West Life Assurance Co. Can now owns 463,209 shares of the company’s stock valued at $29,334,000 after buying an additional 41,589 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Zoetis by 4.7% during the 3rd quarter. Nordea Investment Management AB now owns 26,013 shares of the company’s stock valued at $1,659,000 after acquiring an additional 1,159 shares in the last quarter. NorthCoast Asset Management LLC grew its holdings in shares of Zoetis by 41.1% during the 3rd quarter. NorthCoast Asset Management LLC now owns 382,124 shares of the company’s stock valued at $24,364,000 after acquiring an additional 111,234 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Zoetis by 251.9% during the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after acquiring an additional 1,360 shares in the last quarter. Finally, Davidson Investment Advisors grew its holdings in shares of Zoetis by 18.3% during the 3rd quarter. Davidson Investment Advisors now owns 187,849 shares of the company’s stock valued at $11,977,000 after acquiring an additional 29,047 shares in the last quarter. Institutional investors and hedge funds own 93.33% of the company’s stock.
Shares of Zoetis Inc. (ZTS) traded up $0.12 during trading on Thursday, reaching $70.97. 1,507,400 shares of the company’s stock traded hands, compared to its average volume of 2,772,501. Zoetis Inc. has a twelve month low of $49.79 and a twelve month high of $72.79. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. The firm has a market cap of $34,524.38, a PE ratio of 32.50, a price-to-earnings-growth ratio of 2.12 and a beta of 1.06.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the previous year, the company earned $0.52 EPS. Zoetis’s quarterly revenue was up 8.5% compared to the same quarter last year. equities analysts forecast that Zoetis Inc. will post 2.37 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Thursday, November 9th were given a dividend of $0.105 per share. The ex-dividend date was Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.59%. Zoetis’s dividend payout ratio is presently 22.11%.
Several equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a report on Thursday, October 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Morgan Stanley upped their price objective on shares of Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Finally, Piper Jaffray Companies set a $73.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, August 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $68.24.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.